Phathom Pharmaceuticals financials
$7.36+0.14%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $74.3M | $58.3M | $57.6M | $49.5M | $39.5M | $28.5M | $29.7M | $16.4M | $7.3M | $1.9M | $682.0K | $0.00 |
| Gross profit | $59.2M | $46.3M | $49.9M | $43.3M | $34.5M | $24.8M | $25.8M | $14.0M | $5.9M | $1.5M | $515.0K | $0.00 |
| Gross margin | 79.7% | 79.4% | 86.7% | 87.5% | 87.2% | 86.9% | 87.1% | 85.6% | 81.2% | 77.7% | 75.5% | — |
| Operating income | -$4.0M | -$15.5M | -$5.9M | -$15.3M | -$59.9M | -$78.9M | -$59.4M | -$70.8M | -$77.3M | -$70.0M | -$69.9M | -$35.7M |
| Net income | -$17.6M | -$30.4M | -$21.1M | -$30.0M | -$75.8M | -$94.3M | -$74.5M | -$85.6M | -$91.4M | -$82.9M | -$79.6M | -$43.2M |
| Net margin | −23.7% | −52.1% | −36.7% | −60.5% | −191.9% | −330.7% | −251.0% | −523.3% | −1248.6% | −4333.3% | −11667.2% | — |
| Diluted EPS | $-0.21 | $-0.37 | $-0.29 | $-0.41 | $-1.05 | $-1.31 | $-1.05 | $-1.32 | $-1.56 | $-1.42 | $-1.38 | $-0.76 |
| EBITDA | -$3.9M | -$15.4M | -$5.8M | -$15.1M | -$59.8M | -$78.7M | -$59.2M | -$70.6M | -$77.1M | -$69.7M | -$69.7M | -$35.5M |
| Operating cash flow | -$1.9M | -$15.6M | -$5.0M | -$14.1M | -$62.7M | -$84.9M | -$63.5M | -$63.6M | -$70.7M | -$69.0M | -$43.8M | -$31.9M |
| Free cash flow | -$2.0M | -$15.7M | -$5.1M | -$14.1M | -$62.8M | -$84.9M | -$63.5M | -$63.6M | -$70.8M | -$69.1M | -$44.3M | -$32.9M |
| Diluted shares | 83.7M | 82.1M | 73.8M | 73.4M | 72.5M | 72.0M | 71.1M | 64.6M | 58.6M | 58.4M | 57.5M | 56.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $182.5M | $180.9M | $130.0M | $135.2M | $149.6M | $212.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $166.0M | $165.4M | $210.9M | $208.9M | $206.9M | $205.0M |
| Total assets | $327.1M | $305.1M | $259.1M | $240.3M | $250.2M | $294.2M |
| Total liabilities | $671.3M | $642.1M | $697.3M | $662.8M | $656.1M | $632.6M |
| Shareholders' equity | -$344.3M | -$337.0M | -$438.2M | -$422.5M | -$405.8M | -$338.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology